Compare Abbott Laboratories (ABT) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Estee Lauder Companies Inc — how do they compare? Abbott Laboratories trades at $95.76 (market cap $166.94B), while Estee Lauder Companies Inc trades at $81.3 (market cap $30.55B). The key difference: Abbott Laboratories is far larger — about 5.5× Estee Lauder Companies Inc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | EL | |
|---|---|---|
Market Cap | $166.94B | $30.55B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $119.61 |
52-Week Low | $82.57 | $67.23 |
Enterprise Value | $193.69B | $36.72B |
Dividend Yield | 2.63% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Estée Lauder (EL) trades at $84.44, up 0.87% with a bullish technical signal and recent earnings beats. The stock shows strong momentum with three consecutive quarterly EPS beats and a consensus price target of $90.60. However, fundamentals reveal challenges with negative net income of -$1.13B in 2025 and elevated P/E of 147.8, though gross margins remain robust at 74.71%. Recent news highlights strategic investments and product innovation, including the Scent Scanner launch with Jo Malone London.
The outlook is mixed: technical strength and analyst optimism support upside to $90+, but high valuation and profitability concerns pose risks. Investment opportunity lies in execution of growth initiatives and margin recovery, while key risks include competitive pressures and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
